We didn’t digitize prostate pathology. We transformed the entire prostate cancer diagnostic workflow for better patient care.
Where Conventional Prostate Workflows Lose Precision
Traditional prostate workflows rely on manual tissue handling and fragmented tissue, leading to core disruption, diagnostic subjectivity, and critical delays in patient care.
- Fragile prostate cores often fragment and curl. If tissue is compromised at the bedside, the diagnosis is compromised at the scope.
- Traditional prostate biopsies force histotechnicians into an arduous, high-stress game of “microscopic Tetris,” where they must manually fish out, uncurl, and straighten a dozen fragile, translucent fragments without damaging them further.
- With declining reimbursements, labs and urologists are forced to do more with less.
- In the traditional model, ordering molecular testing requires a separate workflow, manual forms, and a 28-day wait time. This delay leaves patients in “diagnostic limbo.”
- Small tissue samples often result in “Quantity Not Sufficient” (QNS) for molecular testing. Up to 23% of cases are canceled because the tissue was handled too many times before it reached the pathologists
The Lumea Solution: 6 Pillars of the Perfect Workflow
1. Maximizing Core length and Clinical Integrity
Lumea stabilizes cores and preserves orientation at the point of collection, eliminating manual handling and reducing fragmentation by 35%. Research shows this stabilization results in a 31.8% increase in biopsy core length and a 14.5% average increase in tissue surface area on the glass slide, enabling more precise Gleason scoring.
2. Radical Economic Efficiency & ROI
We don’t just replace labor; we transform lab economics. Lumea’s proprietary tissue-handling technology reduces total lab time by 76%. In addition, labs benefit from an 89% reduction in containers, a 136% reduction in formalin usage, and an 83% reduction in stain costs.Grossing that once took 30 minutes now takes five. With more than a threefold reduction in pre-analytical and analytical time, your lab can scale volume without increasing headcount.
3. The Integrated Clinical Outcome
Precision handling leads to precision diagnosis. By ensuring the pathologist receives a superior specimen (with less coiling and folding), the Lumea workflow yields a 9.3% increase in the cancer detection rate (from 49.5% to 58.5%). This results in an 18.8% higher overall CDR compared to traditional manual methods.
4. One-Click Integrated Diagnostics
We’ve collapsed the “Waiting Gap” by embedding molecular ordering directly into the diagnostic viewer. One click, integrated test ordering eliminates most of the manual ordering and shipping process and slashes turnaround times by 64%. We are truly making the minutes count when time is what matters most.
5. Volume-Preserving Pathways
Lumea’s tech has resulted in 2.1x fewer cancelled molecular tests due to QNS and RNA degradation issues. By better preserving the critical tissue volume needed for the genomic insights that determine the patient’s treatment path, Lumea is reducing the trauma and expense incurred from the need for a re-biopsy.
6. The “Gold Standard” Data Foundation
Not all data is created equal. By standardizing the entire workflow starting at the biopsy, Lumea creates high-fidelity, uniform data sets. This provides superior “clean” data for AI training and gives Pharma partners the standardized precision required for clinical trials and advanced treatment decisions.
“By leveraging Lumea technology, we are able to paint a much more accurate picture for patients of what is happening in regards to their cancer.”
– Dr. Ashley Ross, MD, PhD
Northwestern Medical Group Oncologist
Who is Lumea Prostate Built For?
Lumea is the diagnostic standard for high-volume urology groups and pathology practices that refuse to settle for the limitations of legacy workflows.
Large Physician-Owned GU Groups
We empower physician-owners to control the quality of the specimen from the moment it leaves the patient for optimal care with the ultimate feedback loop.
High-Volume GUPath Specialty Labs
For the expert who needs maximum core quality, maintained orientation, and native, prostate-specific AI to manage high-volume caseloads without sacrificing diagnostic precision.
Lab Operations & Ownership
We transform the lab from a labor-heavy cost center into a high-margin powerhouse by automating the most arduous steps of the prostate workflow.
Modern Clinical Research & Pharma Partners
Lumea provides the “Gold Standard” data foundation (standardized, structured, and digital-first) ready for the next generation of AI training and pharmaceutical discovery.
Did You Know? …Fragmentation Is a Diagnostic Failure
In prostate pathology, length equals life! Clinical evidence confirms that biopsy core length is the most significant parameter determining the quality of a biopsy and the subsequent detection of cancer.
- The Length-Detection Correlation: For every 1mm increase in total core length, there is a measurable increase in the probability of detecting prostate cancer. Lumea users have reported a mean sample length longer than the suggested amount for the most accurate diagnosis.
- Fragmentation vs. Risk Stratification: Core fragmentation explains why nearly 30% of prostate cancers are under-staged or under-graded during initial biopsies. Lumea’s 35% reduction in fragmentation is a big deal for getting patients the right treatment, the first time.
- Preventing Tissue Attrition: Traditional processing causes “tissue attrition,” where significant portions of the sample are shaved away during lab “facing.” Lumea’s process eliminates linear variability, putting 14.5% more tissue surface area on the slide while utilizing less of the block.
- Maintaining Orientation: Lumea’s simple and easy way to maintain core orientation means a much more accurate, pin-pointed diagnosis for better treatment planning and better patient care.
Ready to See Better Prostate Workflows?
Discover how Lumea Prostate enables the best patient care possible.
